The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- E&C HHS Budget Hearing Grazes Biopharma Issues But Focus on King v. Burwell Contingency Plan Intensifies Feb. 26, 2015
- Tiered Formularies In Exchange Plans, 340B User Fees, Rx Drug Abuse Highlighted At House HHS Approps Hearing Feb. 25, 2015
- Avedro CXL Therapy Clears FDA Committee: “Abysmal” Study Good Enough For Approval Vote; Still Uncertainty At FDA Feb. 25, 2015
See More Research Notes